HeartBeam Launches New Video Showcasing the HeartBeam AIMI™ and AIMIGo™ Technologies
September 20 2022 - 8:31AM
Business Wire
Reminder: Company to Host Virtual Roadshow
Webinar on Tuesday, September 20, 2022 at 4:30 p.m. Eastern
Time
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology
company that has developed the first and only 3D-vector ECG
platform for heart attack detection anytime, anywhere, today
announced that in conjunction with an upcoming virtual roadshow
webinar taking place Tuesday, September 20, 2022, at 4:30 p.m. ET,
it has released a new video that takes viewers behind the scenes
for a featured look at the HeartBeam AIMIGo technology and will be
shown to viewers of the webcast.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220920005147/en/
New Video Showcasing the HeartBeam AIMI™
and AIMIGo™ Technologies (Graphic: Business Wire)
The video explores the HeartBeam AIMIGo technology, need, market
opportunity and use in heart attack detection. AIMIGo is the first
and only credit card-sized 12-lead output ECG device for remote
heart attack detection with a 510(K) regulatory pathway. The
Company expects to submit AIMIGo to the US Food and Drug
Administration (FDA) for clearance by the end of the year. Once
cleared the Company believes that AIMIGo can enable patients and
their clinicians, for the first time outside of a medical setting,
to determine if symptoms are due to a heart attack, quickly and
easily, so care can be initiated, if needed. The goal of
HeartBeam’s technology is to offer more accurate heart attack
detection to triage patients, expedite treatment and save
healthcare dollars.
The video is available in the company’s
investor relations section here.
“This new video provides a compelling overview and explanation
of our technologies and highlights our continued progress toward
making the AIMIGo device available for remote heart attack
detection,” said Branislav Vajdic, PhD, HeartBeam CEO and founder.
“We look forward to sharing the video at our upcoming webinar along
with recent announcements, ongoing initiatives and key 2022 and
2023 milestones.”
HeartBeam’s CEO and founder Branislav Vajdic, PhD, CFO Rick
Brounstein, and Chief Business Officer Jon Hunt, PhD, will host a
virtual roadshow webinar, during which they will review recent
announcements, including the Company’s 510(k) application to the
FDA for its HeartBeam AIMI platform technology, newly issued patent
for a 12-lead electrocardiogram (ECG) patch monitor, ongoing
initiatives and discuss key 2022 and 2023 milestones. The webinar
will be accompanied by a presentation and followed by a
question-and-answer session from webcast viewers, which can be
accessed via the webcast link.
HeartBeam AIMI and AIMIGo have not yet been cleared by the FDA
for marketing in the USA or other geographies.
To access the webinar, please use the following information:
Date:
Tuesday September 20, 2022
Time:
4:30 p.m. Eastern time (1:30 p.m. Pacific
time)
Dial-in:
1-877-704-4453
International Dial-in:
1-201-389-0920
Conference Code:
13732771
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1569585&tp_key=156ad0b0f4
A telephone replay will be available approximately two hours
after the call and will run through December 20, 2022, by dialing
1-844-512-2921 from the U.S., or 1-412-317-6671 from international
locations, and entering replay pin number: 13732771. The replay can
also be viewed through the webinar webcast link above and the
presentation utilized during the call will be available in the
company’s investor relations section here.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company
that has developed the first and only 3D-vector ECG platform for
heart attack detection anytime, anywhere. By applying a suite of
proprietary algorithms to simplify vector electrocardiography
(VECG), the HeartBeam platform enables patients and their
clinicians to determine if symptoms are due to a heart attack,
quickly and easily, so care can be expedited, if required.
HeartBeam has two patented products in development. HeartBeam AIMI
is software for acute care settings that provides a 3D comparison
of baseline and symptomatic 12-lead ECG to more accurately identify
a heart attack. HeartBeam AIMIGo is the first and only credit
card-sized 12-lead output ECG device coupled with a smart phone app
and cloud-based diagnostic software system to facilitate remote
heart attack detection. HeartBeam AIMI and AIMIGo have not yet been
cleared by the US Food and Drug Administration (FDA) for marketing
in the USA or other geographies. For more information, visit
HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our in our Forms 10-K, 10-Q and other reports filed with the SEC
and available at www.sec.gov. We urge you to consider those risks
and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220920005147/en/
Media and Investor Relations Contact: Chris Tyson
Executive Vice President MZ North America Direct: 949-491-8235
BEAT@mzgroup.us www.mzgroup.us
Media Contact: Capwell Communications
media@capwellcomm.com 949-999-3303
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Sep 2024 to Oct 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Oct 2023 to Oct 2024